Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC
/in Dendritic Cells, International Publications, NSCLC /von 2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-202Hematologic neoplasms: Dendritic cells vaccines in motion
/in Dendritic Cells, International Publications /von 2017-09-12 / Clin. Immunol. 2017 10;183:181-190Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2017-08-22 / Blood 2017 10;130(15):1713-1721Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-08-01 / Melanoma Res 2017 08;27(4):351-357Recent developments in immunotherapy of acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International Publications /von 2017-07-25 / J Hematol Oncol 2017 07;10(1):142Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-06-27 / Oncotarget 2017 Sep;8(40):67439-67456A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2017-06-20 / Oncotarget 2017 Jun;8(25):41538-41548Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Urothelial Carcinoma /von 2017-06-07 / Biomed Res Int 2017;2017:5618174
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de